@article{ref1,
title="Rapid treatments for depression: Endocannabinoid system as a therapeutic target",
journal="Neuroscience and biobehavioral reviews",
year="2022",
author="Sharafi, AmirMohammad and Pakkhesal, Sina and Fakhari, Ali and Khajehnasiri, Nazli and Ahmadalipour, Ali",
volume="137",
number="",
pages="e104635-e104635",
abstract="Current first-line treatments for major depressive disorder (MDD), i.e., antidepressant drugs and psychotherapy, show delayed onset of therapeutic effect as late as 2-3 weeks or more. In the clinic, the speed of beginning of the actions of antidepressant drugs or other interventions is vital for many reasons. Late-onset means that depression, its related disability, and the potential danger of suicide remain a threat for some patients. There are some rapid-acting antidepressant interventions, such as sleep deprivation, ketamine, acute exercise, which induce a significant response, ranging from a few hours to maximally one week, and most of them share a common characteristic that is the activation of the endocannabinoid (eCB) system. Activation of this system, i.e., augmentation of eCB signaling, appears to have anti-depressant-like actions. This article puts the idea forward that the activation of eCB signaling represents a critical mechanism of rapid-acting therapeutic interventions in MDD, and this system might contribute to the development of novel rapid-acting treatments for MDD.<p /><p>Language: en</p>",
language="en",
issn="0149-7634",
doi="10.1016/j.neubiorev.2022.104635",
url="http://dx.doi.org/10.1016/j.neubiorev.2022.104635"
}